’Covishield shouldn’t have been rolled out’: Eminent doctor flags vaccine over ’severe side effects’

According to Dr Aseem Malhotra, the vaccine manufactured in India by the Serum Institute is ‘even worse’ than mRNA COVID-19 vaccines when it came to concerns such as heart attacks and strokes.

Edited By Anwesha Mitra
Updated10 Feb 2023, 03:00 PM IST
The World Health Organization had greenlit the use of Covishield two years ago for individuals aged 18 and older.
The World Health Organization had greenlit the use of Covishield two years ago for individuals aged 18 and older. (HT_PRINT)

A well known British-Indian cardiologist has flagged the cardiovascular side effects of the Covishield vaccine. According to Dr Aseem Malhotra, the vaccine manufactured in India by the Serum Institute is ‘even worse’ than mRNA COVID-19 vaccines when it came to concerns such as heart attacks and strokes. For the uninitiated, the Oxford-AstraZeneca jab - one of the first to be introduced in India - is presently approved for a two-dose regime and a booster shot. 

The World Health Organization had greenlit the use of Covishield two years ago for individuals aged 18 and older. 

According to Dr Malhotra, however, the vaccine "should never have been rolled out in the country in the first place". As he put it, “the more shots you have the greater the chance of suffering a serious side effect”.

The cardiologist who has been leading international calls for the suspension of mRNA COVID-19 jabs demanded a full safety review into the use of Covishield. Citing a comparison (done till June 2021) published in a peer-reviewed journal, he said that the Oxford-AstraZeneca vaccine was far worse than Pfizer's mRNA jab in terms of cardiovascular effects, heart attacks, strokes and even deaths.

“Why was AstraZeneca's Covishield administered in India when it was suspended in the UK and some European countries due to severe side-effects? There needs to be immediate suspension pending inquiry as to why India got this so very very wrong,” he said.

Also read: Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India

As vaccines against COVID-19 first emerged, a slew of countries had suspended the Oxford-AstraZeneca jab - including Denmark, the Netherlands, Thailand, Germany, France, Italy, and Spain. There were disconcerting reports that a small number of recipients have experienced blood clots, some fatal.

“The vaccine is safe and effective for all individuals aged 18 and above...The Astra-Zeneca vaccine can be offered to people who have had COVID-19 in the past. But individuals may choose to delay vaccination for 3 months following the infection,” reads the vaccine profile on the World Health Organization website.

According to the doctor, there have been an ‘unprecedented’ number of adverse reports when it came to the Oxford-AstraZeneca vaccine. “8,00,000 reports of adverse effects which were beyond mild after administering 9.7 million doses,” he asserted.

Also read: Draft WHO pandemic deal pushes for equity to avoid COVID 'failure' repeat

While it is a tad late in the day to troubleshoot or withdraw a COVID-19 vaccine, Dr Malhotra insisted that it was necessary to 'compensate many many people suffering from vaccine induced injuries' or those who have lost relatives.

More than 90% of the country exposed to COVID-19,accquiring a strong natutal immunity to the virus. “There is no further requirement of vaccination for anybody in India. And there's certainly no requirement for anyone to have a booster especially as we know the side-effect are incremental,” Dr Malhotra asserted.

(With inputs from PTI)

Catch all the Business News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:10 Feb 2023, 03:00 PM IST
Business NewsNewsIndia’Covishield shouldn’t have been rolled out’: Eminent doctor flags vaccine over ’severe side effects’

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    HDFC Bank share price

    1,682.15
    03:59 PM | 3 OCT 2024
    -44 (-2.55%)

    Reliance Industries share price

    2,815.25
    03:58 PM | 3 OCT 2024
    -114.55 (-3.91%)

    Tata Steel share price

    166.95
    03:59 PM | 3 OCT 2024
    -0.05 (-0.03%)

    Tata Motors share price

    926.00
    03:59 PM | 3 OCT 2024
    -39.35 (-4.08%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Amber Enterprises India share price

    5,170.45
    03:57 PM | 3 OCT 2024
    325.35 (6.72%)

    Petronet LNG share price

    364.30
    03:56 PM | 3 OCT 2024
    20.05 (5.82%)

    Jubilant Ingrevia share price

    819.30
    03:40 PM | 3 OCT 2024
    44.1 (5.69%)

    Angel Broking share price

    2,739.65
    03:40 PM | 3 OCT 2024
    139.6 (5.37%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      77,475.00560.00
      Chennai
      77,481.00560.00
      Delhi
      77,633.00560.00
      Kolkata
      77,485.00560.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.86/L0.00
      Chennai
      100.75/L0.00
      Kolkata
      104.95/L0.00
      New Delhi
      94.72/L0.00

      Popular in News

        HomeMarketsPremiumInstant LoanMint Shorts